General Information
Drug ID
DR00030
Drug Name
Atorvastatin
Synonyms
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; Atogal; Atorlip; Atorpic; Atorvastatin (INN); Atorvastatin [INN:BAN]; Atorvastatina; Atorvastatine; Atorvastatinium; Atrovastin; Cardyl; Faboxim; Lipitor (TN); Lipitor(TM); Lipotropic; Lipovastatinklonal; Liprimar; Lowden; Sincol; Sortis; Sortis (TN); Sotis; Torvacard; Torvast; Totalip; Tozalip; Tulip; Vastina; Xanator; Xarator; Xavator; Zurinel
Drug Type
Small molecular drug
Indication Heart attack [ICD11: BA41.Z] Approved [1]
Dyslipidaemias [ICD11: 5C8Z] Approved [1]
Hyperlipidaemia [ICD11: 5C8Z] Approved [1]
Therapeutic Class
Anticholesteremic Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=60823"></iframe>
3D MOL 2D MOL
Formula
C33H35FN2O5
Canonical SMILES
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
InChI
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
InChIKey
XUKUURHRXDUEBC-KAYWLYCHSA-N
CAS Number
CAS 134523-00-5
Pharmaceutical Properties Molecular Weight 558.65 Topological Polar Surface Area 112
Heavy Atom Count 41 Rotatable Bond Count 12
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 6
PubChem CID
60823
PubChem SID
103554720 , 104178840 , 104321734 , 104829550 , 117367061 , 124892211 , 126525305 , 126624171 , 126658151 , 126682126 , 127315782 , 127315783 , 127315784 , 127315785 , 127315786 , 127315787 , 127315788 , 127315789 , 127315790 , 127315791 , 127315792 , 127315793 , 14910832 , 26684326 , 26697359 , 29215408 , 43118161 , 49845979 , 50037926 , 51091801 , 53787715 , 56311281 , 56311722 , 56311943 , 56311969 , 56312802 , 56313042 , 56313334 , 56313578 , 56314463 , 57314133 , 75432172 , 7884979 , 7978735 , 8187078 , 822166 , 85856289 , 9052 , 92714388 , 93166494
ChEBI ID
ChEBI:39548
TTD Drug ID
D01QIN
DT(s) Transporting This Drug MCT1 Transporter Info Monocarboxylate transporter 1 Substrate [2]
MCT2 Transporter Info Monocarboxylate transporter 2 Substrate [3]
OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [4]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [5]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [6]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [7]
P-GP Transporter Info P-glycoprotein 1 Substrate [8]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OATP1B1 Transporter Info Km = 0.77 microM Human embryonic kidney cells (HEK293)-OATP1B1 [9]
OATP1B1 Transporter Info Km = 12.4 microM Human embryonic kidney cells (HEK293)-OATP1B1 [10]
OATP1B1 Transporter Info Km = 18.9 microM Human embryonic kidney cells (HEK293)-OATP1B1 [11]
OATP1B3 Transporter Info Km = 0.73 microM Human embryonic kidney cells (HEK293)-OATP1B3 [9]
OATP2B1 Transporter Info Km = 2.84 microM Human embryonic kidney cells (HEK293)-OATP2B1 [9]
OATP2B1 Transporter Info Km = 0.2 microM Madin-Darby canine kidney cells (MDCKII)-OATP2B1 [12]
References
1 Ramipril was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
3 Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
4 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
5 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
6 FDA Drug Development and Drug Interactions
7 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
8 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
9 Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63.
10 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.
11 effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):194-204.
12 Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006 Dec;80(6):607-20.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.